Le Lézard
Classified in: Health
Subjects: PDT, SVY, TDS, TRI

PathomIQ's AI-powered tool shows promise in assessing risk for metastasis in non-metastatic castration-resistant prostate cancer (nmCRPC)

CUPERTINO, Calif., June 6, 2023 /PRNewswire/ -- New data released today at the American Society of Clinical Oncology (ASCO) Annual Meeting highlighted the application of PathomIQ Inc.'s PATHOMIQ_PRAD AI test to assess the risk for metastasis in non-metastatic castration-resistant prostate cancer (nmCRPC).

PathomIQ is a leading provider of AI-enabled solutions that leverage digitized H&E slides to discover novel biomarkers that predict response to therapy, inform drug discovery, de-risk clinical trials and enable precision medicine in clinical practice. PATHOMIQ_PRAD was developed as an AI-enabled prognostic algorithm that predicts the risk of metastasis from Whole Slide Images (WSIs) of H&E-stained core biopsies or radical prostatectomy specimens.

Most patients with prostate cancer treated with androgen deprivation therapy (ADT) for progressive disease will experience progression to CRPC. APA (ERLEADA®)* is approved for the treatment of patients with nmCRPC and metastatic castration sensitive prostate cancer (mCSPC).

The objective of this study was to determine the risk for metastasis in patients with nmCRPC based on PATHOMIQ_PRAD risk categories. Patients in the Phase 3 SPARTAN clinical trial with available H&E-stained slides from their primary diagnosis were included in this study. The study showed that PATHOMIQ_PRAD score could have prognostic value in identifying patients at high risk of metastatic progression in nmCRPC setting. All patients receiving APA + ADT had significantly improved metastasis-free survival (MSF) compared with patients receiving ADT alone.

"We are honored to be collaborating with Janssen and working closely with their team to evaluate H&E-based AI as a potential tool for prognostic risk stratification in nmCRPC patients. Our PATHOMIQ_PRAD AI model has been successfully validated at multiple medical institutions, and we are working to make it clinically available in the near future," said Dr George Wilding, Chief Medical Officer, PathomIQ Inc.

The results were shared at the poster session Genitourinary Cancer ? Prostate, Testicular, and Penile Abstract #5027, Poster Board #121, "AI-enabled analysis of H&E-stained prostate cancer tissue images: Assessing risk for metastasis prior to apalutamide (APA) treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC)."

To learn more about PathomIQ Inc., please visit www.pathomiq.com

* ERLEADA (apalutamide) is a product of Janssen Biotech, Inc.

SOURCE PathomIQ Inc.

These press releases may also interest you

23 sep 2023
The flow diversion aneurysm treatment market size is expected to grow by USD 2.11 billion from 2022 to 2027. In addition, the momentum of the market will be progressing at a CAGR of  8.8% during the forecast period, according to Technavio Research....

23 sep 2023
The dietary supplements market size is expected to grow by USD 61.4 billion from 2022 to 2027, according to Technavio. In addition, the growth momentum of the market will progress at a CAGR of 8.16% during the forecast period. Increasing adoption of...

23 sep 2023
African Union Heads of State and Government, global health leaders and development partners...

23 sep 2023
In the news release, Public-sector contract talks - Tens of thousands demonstrate in Montréal to defend public services, issued 23-Sep-2023 by Alliance du personnel professionnel et technique de la santé et des services sociaux (APTS) over PR...

23 sep 2023
More than 7,500 participants took a giant step forward for youth mental health today, crossing the finish line for the 11th anniversary of RBC Race for the Kids in Toronto. Collectively they raised $2.5 million in support of Family Navigation Project...

23 sep 2023
On September 23, 2023, oncologists and experts from more than 60 clinical research centers across the country gathered in Guangzhou to participate in the YL201 Phase I/II Investigators Meeting hosted by Suzhou MediLink Therapeutics Co., Ltd. The...

News published on and distributed by: